IP Verse

Modified Oncolytic Virus - EP3400293

The patent EP3400293 was granted to Replimune on Jul 12, 2023. The application was originally filed on Jan 9, 2017 under application number EP17701910A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3400293

REPLIMUNE
Application Number
EP17701910A
Filing Date
Jan 9, 2017
Status
Patent Maintained As Amended
Jun 9, 2023
Grant Date
Jul 12, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MARGARET DIXONJun 7, 2021MEWBURN ELLISADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2011044953
DESCRIPTIONUS2015283234
DESCRIPTIONWO2007123737
DESCRIPTIONWO2014066532
INTERNATIONAL-SEARCH-REPORTWO2006002394
OPPOSITIONEP1235853
OPPOSITIONUS7981669
OPPOSITIONUS8679830
OPPOSITIONWO2005011715
OPPOSITIONWO2006002394
OPPOSITIONWO2007052029
OPPOSITIONWO2015077624
OPPOSITIONWO2017118864
OTHERUS7959925
OTHERUS7981669
OTHERUS8679830
OTHERWO2005011715
OTHERWO2007052029
OTHERWO2015077624

Non-Patent Literature (NPL) Citations (44) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHOU ET AL., SCIENCE, (1990), vol. 250, pages 1262 - 1266-
DESCRIPTION- LIU ET AL., GENE THERAPY, (2003), vol. 10, pages 292 - 303-
DESCRIPTION- MACLEAN ET AL., J. GEN. VIROL., (1991), vol. 72, pages 631 - 639-
INTERNATIONAL-SEARCH-REPORT- Geoffrey Thomas Gibney, "Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. | 2014 ASCO Annual Meeting | Abstracts | Meeting Library", (20040501), URL: http://meetinglibrary.asco.org/content/127143-144, (20170222), XP055348796 [A] 1-16,18-20,22-46 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- Piasecki et al., "Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade.", (20150419), URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=ebc7290a-af22-4fa6-9436-c276011fb181&cKey=b61c1150-5517-456b-acd3-2f8048807587&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424, (20170222), XP055348530 [X] 1-16,18-20,22-46 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- LIU B L ET AL, "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20030201), vol. 10, no. 4, doi:10.1038/SJ.GT.3301885, ISSN 0969-7128, pages 292 - 303, XP002313120 [A] 1-16,18-20,22-46 * page 299, column l * * page 295 * * figure 2 *
INTERNATIONAL-SEARCH-REPORT- YAN WEN ET AL, "Developing novel oncolytic adenoviruses through bioselection", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20030201), vol. 77, no. 4, doi:10.1128/JVI.77.4.2640-2650.2003, ISSN 0022-538X, pages 2640 - 2650, XP002394479 [A] 1-16,18-20,22-46 * abstract * * page 2642, column r, paragraph 2 full *
INTERNATIONAL-SEARCH-REPORT- G. R. SIMPSON, "Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control", CANCER RESEARCH, (20060501), vol. 66, no. 9, doi:10.1158/0008-5472.CAN-05-4352, ISSN 0008-5472, pages 4835 - 4842, XP055113042 [X] 1-16,18-20,22-46 * abstract * * page 4835, column r, paragraph l *
INTERNATIONAL-SEARCH-REPORT- N. N. SENZER ET AL, "Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma", JOURNAL OF CLINICAL ONCOLOGY, (20091102), vol. 27, no. 34, doi:10.1200/JCO.2009.24.3675, ISSN 0732-183X, pages 5763 - 5771, XP055207592 [A] 1-16,18-20,22-46 * page 5763, column r *
INTERNATIONAL-SEARCH-REPORT- NICOLAS SOKOLOWSKI ET AL, "Oncolytic virotherapy using herpes simplex virus: how far have we come?", ONCOLYTIC VIROTHERAPY, (20151101), doi:10.2147/OV.S66086, page 207, XP055347641 [X] 1-16,18-20,22-46 * tables 1-3 * * page 210, column r *
OPPOSITION- Anonymous, "Metastasis", Dictionary.com, (20220101), pages 1 - 5, Dictionary.com, URL: https://www.dictionary.com/browse/metastasis, (20221010), XP055969170-
OPPOSITION- BATEMAN et al., "FUSOGENIC MEMBRANE GLYCOPROTEINS AS A NOVEL CLASS OF GENES FOR THE LOCAL AND IMMUNE-MEDIATED CONTROL OF TUMOR GROWTH", Cancer Res., (20000315), vol. 60, no. 6, pages 1492 - 7, XP002906944-
OPPOSITION- BATEMAN et al., "VIRAL fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.", Cancer Res., (20021115), vol. 62, no. 22, pages 6566 - 78, XP002542043-
OPPOSITION- Encyclopedia of Neuroscience excerpt-
OPPOSITION- GIBNEY et al., "Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. | 2014 ASCO Annual Meeting | Abstracts | Meeting Library", J Clin Oncol, (20140000), vol. 32, no. 15, page 3010, XP055348796-
OPPOSITION- HOFFMANN et al., "Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia", World J Gastroenterol, (20080328), vol. 14, no. 12, pages 1842 - 1850, XP055815776-
OPPOSITION- HOFFMANN et al., "In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines", World J Gastroenterol, (20070614), vol. 13, no. 22, pages 3063 - 70, XP055815775-
OPPOSITION- LI et al., "AN INTERCONNECTION NETWORK AND A ROUTING SCHEME FOR A MASSIVELY PARALLEL MESSAGE-PASSING MULTICOMPUTER *.", Int. J. Cancer, (20080000), vol. 123, pages 493 - 499, XP00268933-
OPPOSITION- PIASECKI et al., "Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade.", Cancer Res, (20150000), vol. 75, no. 15 Suppl, XP055348530-
OPPOSITION- HASWELL et al., "Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154.", Eur J Immunol, (20010000), vol. 31, pages 3094 - 3100, XP002247462
OPPOSITION- KANAGAVELU et al., "Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine", Vaccine, (20120000), vol. 30, pages 691 - 701, XP028434514
OPPOSITION- HUANG et al., "Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL", Mol Ther, vol. 18, no. 2, pages 264 - 274, XP055594765
OPPOSITION- Matveeva Olga V, Guo Zong S, Shabalina Svetlana A, Chumakov Peter M, "Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency", Molecular Therapy - Oncolytics, (20150101), vol. 2, doi:10.1038/mto.2015.11, ISSN 2372-7705, page 15011, XP055908476
OPPOSITION- LIU et al., "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.", Gene Therapy, (20030000), vol. 10, pages 292 - 303, XP002313120
OPPOSITION- TERADA et al., "Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models", Gene Therapy, (20060000), vol. 13, pages 705 - 714, XP002448244
OPPOSITION- YAN et al., "Developing novel oncolytic adenoviruses through bioselection.", J Virol, (20030000), vol. 77, no. 4, pages 2640 - 2650, XP002394479
OPPOSITION- EBERT O, ET AL, "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.", Cancer research, American Association for Cancer Research, 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas , (20040501), vol. 64, no. 9, doi:10.1158/0008-5472.CAN-03-3753, ISSN 0008-5472, pages 3265 - 3270, XP002384970
OPPOSITION- SIMPSON et al., "Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control", Cancer Res, (20060000), vol. 6, no. 9, page 4835, XP055113042
OPPOSITION- YI et al., "Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo", Cancer Res, (20070000), vol. 67, no. 20, pages 10027 - 10037, XP055594761
OPPOSITION- KIM et al., "Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand", Cancer Res, (20090000), vol. 69, no. 21, pages 8516 - 8525, XP055594760
OPPOSITION- Hoffmann Dennis, Bayer Wibke, Grunwald Thomas, Wildner Oliver, "Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20070701), vol. 6, no. 7, doi:10.1158/1535-7163.MCT-06-0790, ISSN 1535-7163, pages 1942 - 1950, XP055969167
OPPOSITION- SENZER et al., "Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma", J Clin Oncol, (20090000), vol. 27, no. 34, pages 5763 - 5771, XP055207592
OPPOSITION- KANAGAVELU et al., "HIV-1 Adenoviral Vector Vaccines Expressing Multi-Trimeric BAFF and 4-1BBL Enhance T Cell Mediated Anti-Viral Immunity", PlosOne, (20140000), vol. 9, no. 2, page e90100, XP055132482
OPPOSITION- SOKOLOWSKI et al., "Oncolytic virotherapy using herpes simplex virus: how far have we come?", Oncol Virol, (20150000), vol. 4, pages 20 7 - 219, XP055347641
OPPOSITION- Karishma Rajani, Richard Vile, "Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors", Viruses, (20151113), vol. 7, no. 11, doi:10.3390/v7112914, pages 5889 - 5901, XP055522949
OPPOSITION- Todo, "“Armed” oncolytic herpes simplex viruses for brain tumor therapy", Cell Adhesion & Migration, (20080000), vol. 2, no. 3, pages 208 - 213, XP055594753
OTHER- Linsey E. Haswell et al, "Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154", Eur. J. lmmunol., vol. 31, no. 10, (20011001), pages 3094 - 3100, XP002247462
OTHER- Saravana K. Kanagavelua et al, "Soluble multi-trimeric INF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine", Vaccine, vol. 30, no. 4, (20121122), pages 691 - 702, XP028434514
OTHER- Jing-Hua Huang et al, "Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1 BBL", MOLECULAR THERAPY, vol. 18, no. 2, (20100201), pages 264 - 274, XP055594765
OTHER- Terada K. et al, "Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models", Gene Therapy, vol. 13, no. 8, (20060401), pages 705 - 714, XP002448244
OTHER- Kyung H. Yi et al, "Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivoUsing Herpes Simplex Virus Amplicons Encoding 4-1 BBL Persistin the Host and Show Antitumor Activity In vivo", Cancer Res, vol. 67, no. 20, (20071015), pages 10027 - 10037, XP055594761
OTHER- Hong Sung Kim et al, "Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1 BB Ligand", Cancer Res, vol. 69, no. 21, (20091101), pages 8516 - 8525, XP055594760
OTHER- Saravana Kanagavelu et al, "HIV-1 Adenoviral Vector Vaccines ExpressingMulti-Trimeric BAFF and 4-1 BBL Enhance T Cell MediatedAnti-Viral Immunity", PLOS ONE, vol. 9, no. 2, (20140228), page e90100, XP055132482
OTHER- Tomoki Todo, ""Armed" oncolytic herpes simplex viruses for brain tumor therapy", Cell Adhesion & Migration, vol. 2, no. 3, (20080701), pages 208 - 213, XP055594753

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents